Probiotics in cirrhosis: Do we expect too much?

Liver International

Volumn 33, Issue 10, 2013, Pages 1451-1453

  Soriano, German ^a   Guarner, Carlos ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NORFLOXACIN; PLACEBO; PROBIOTIC AGENT; PROPRANOLOL;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BACILLUS COAGULANS; BACILLUS PUMILUS; BACTERIAL TRANSLOCATION; BACTERIUM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLOSTRIDIUM BUTYRICUM; DECOMPENSATED LIVER CIRRHOSIS; EDITORIAL; ENDOTOXEMIA; ESCHERICHIA COLI; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LEUCONOSTOC MESENTEROIDES; LIVER CIRRHOSIS; NONHUMAN; PEDIACOCCUS PENTOSECEUS; PORTAL HYPERTENSION; STREPTOCOCCUS THERMOPHILUS;

BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; HUMANS; LIVER CIRRHOSIS; PROBIOTICS;

EID: 84885166881     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12288     Document Type: Editorial

References (26)

1. Sanders ME, Guarner F, Guerrant R, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013; 62: 787-96.
2. Jonkers D, Stockbrügger R. Review article: probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 133-48.
3. Lata J, Jurankova J, Kopacova M, et al. Probiotics in hepatology. World J Gastroenterol 2011; 17: 2890-6.
4. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 27-31.
5. Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-9.
6. Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
7. Bauer TM, Fernández J, Navasa M, et al. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002; 36: 501-6.
8. Soriano G, Sánchez E, Guarner C, et al. Lactobacillus johnsonii La1 without antioxidants do not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. J Hepatol 2012; 57: 1395-6.
9. Wiest R, Chen F, Cadelina G, et al. Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 2003; 48: 1136-41.
10. Dhiman RK. Gut microbiota and hepatic encephalopathy. Metab Brain Dis 2013; 28: 321-6.
11. McGee RG, Bakens A, Wiley K, et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011; 11: CD008716.
12. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9.
13. Sharma P, Sharma BC, Puri V, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008; 20: 506-11.
14. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107: 1043-50.
15. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3.
16. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-15.
17. Malaguarnera M, Gargante MP, Malaguarnera G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206.
18. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
19. Lunia MK, Sharma BC, Sachdeva S, et al. An open label randomised controlled trial of probiotics for primary prophylaxis of hepatic encephalopathy in patients with cirrhosis. J Hepatol 2013; 58(Suppl.1): S35(abstract).
20. Jayakumar S, Carbonneau M, Hotte N, et al. VSL#3 probiotic therapy does not reduce portal pressure in patients with decompensated cirrhosis. Liver Int 2013; 33: 1470-7.
21. Tandon P, Moncrief K, Madsen K, et al. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 2009; 29: 1110-5.
22. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-8.
23. Kühbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006; 55: 833-41.
24. Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int 2013; 33: 1148-57.
25. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized trial. Eur J Gastroenterol Hepatol 2012; 24: 831-9.
26. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.